Takeda
Tempus, Takeda Expand Collaboration to Use Multimodal Data for Oncology R&D
Takeda will use Tempus' multimodal datasets and biological modeling capabilities in its cancer therapeutic development work.
BostonGene, Takeda Form Immunotherapy Clinical Research Partnership
The firms will apply BostonGene's AI-driven multiomics platform to identify molecular drivers of cancer and predictive markers of treatment response.
Takeda Acquires Exclusive Option to Globally License AC Immune's Alzheimer's Therapies
AC Immune received $100 million upfront and is eligible for up to $2.1 billion in milestone payments, royalties, and other fees.
An advisory committee on Friday will consider whether minimal residual disease can reliably predict if multiple myeloma drugs are benefiting patients.
Takeda Nets FDA Accelerated Approval for Frontline Iclusig, Chemo Combo in Certain ALL Patients
The FDA approved the drug combination for Philadelphia chromosome-positive acute lymphoblastic leukemia based on the Phase III PhALLCON trial.
Sep 30, 2022